PL2151436T3 - Nowe pochodne 1,2,3,4-tetrahydrochinoksaliny, które jako podstawnik zawierają grupę fenylową z wprowadzoną strukturą estru kwasu sulfonowego lub amidu kwasu sulfonowego i które mają aktywność wiążącą wobec receptora glukokortykoidowego - Google Patents

Nowe pochodne 1,2,3,4-tetrahydrochinoksaliny, które jako podstawnik zawierają grupę fenylową z wprowadzoną strukturą estru kwasu sulfonowego lub amidu kwasu sulfonowego i które mają aktywność wiążącą wobec receptora glukokortykoidowego

Info

Publication number: PL2151436T3
Authority: PL; Poland
Prior art keywords: sulfonic acid; substituent; novel; phenyl group; binding activity
Prior art date: 2007-05-29

Application number

PL08764835T

Other languages

English (en)

Inventor

Mamoru Matsuda

Toshiyuki Mori

Masato Nagatsuka

Sachiko Kobayashi

Masatomo Kato

Miwa Takai

Original Assignee

Santen Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-29

Filing date

2008-05-29

Publication date

2013-09-30

2008-05-29 Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd

2013-09-30 Publication of PL2151436T3 publication Critical patent/PL2151436T3/pl

Links

HORKYAIEVBUXGM-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoxaline Chemical class C1=CC=C2NCCNC2=C1 HORKYAIEVBUXGM-UHFFFAOYSA-N 0.000 title 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 title 1
102000003676 Glucocorticoid Receptors Human genes 0.000 title 1
108090000079 Glucocorticoid Receptors Proteins 0.000 title 1
230000027455 binding Effects 0.000 title 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
125000001424 substituent group Chemical group 0.000 title 1
125000002130 sulfonic acid ester group Chemical group 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hematology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Otolaryngology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

PL08764835T 2007-05-29 2008-05-29 Nowe pochodne 1,2,3,4-tetrahydrochinoksaliny, które jako podstawnik zawierają grupę fenylową z wprowadzoną strukturą estru kwasu sulfonowego lub amidu kwasu sulfonowego i które mają aktywność wiążącą wobec receptora glukokortykoidowego PL2151436T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2007141568		2007-05-29
EP08764835.8A EP2151436B1 (en)	2007-05-29	2008-05-29	Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
PCT/JP2008/059866 WO2008146871A1 (ja)	2007-05-29	2008-05-29	グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規１，２，３，４－テトラヒドロキノキサリン誘導体

Publications (1)

Publication Number	Publication Date
PL2151436T3 true PL2151436T3 (pl)	2013-09-30

Family

ID=40075104

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL08764835T PL2151436T3 (pl)	2007-05-29	2008-05-29	Nowe pochodne 1,2,3,4-tetrahydrochinoksaliny, które jako podstawnik zawierają grupę fenylową z wprowadzoną strukturą estru kwasu sulfonowego lub amidu kwasu sulfonowego i które mają aktywność wiążącą wobec receptora glukokortykoidowego

Country Status (14)

Country	Link
US (2)	US8193187B2 (pl)
EP (1)	EP2151436B1 (pl)
JP (1)	JP5183302B2 (pl)
KR (1)	KR20100022456A (pl)
CN (1)	CN101679317B (pl)
AU (1)	AU2008255733B8 (pl)
BR (1)	BRPI0811262A2 (pl)
CA (1)	CA2687948A1 (pl)
ES (1)	ES2419239T3 (pl)
MX (1)	MX2009012885A (pl)
NZ (1)	NZ581666A (pl)
PL (1)	PL2151436T3 (pl)
RU (1)	RU2498980C2 (pl)
WO (1)	WO2008146871A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101400659B (zh)	2006-03-14	2012-02-29	参天制药株式会社	具有糖皮质激素受体结合活性的新型1，2，3，4-四氢喹喔啉衍生物
EP2151436B1 (en) *	2007-05-29	2013-04-24	Santen Pharmaceutical Co., Ltd	Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
US20090042936A1 (en) *	2007-08-10	2009-02-12	Ward Keith W	Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
GEP20135804B (en) *	2008-09-12	2013-04-10	Santen Pharmaceutical Co Ltd	Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group having sulfonic acid ester introduced therein as substituent
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2665716B1 (en)	2011-01-21	2017-03-08	Eisai R&D Management Co., Ltd.	Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
US20120316199A1 (en)	2011-06-07	2012-12-13	Ward Keith W	Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
IN2014DN06911A (pl)	2012-01-31	2015-05-15	Santen Pharmaceutical Co Ltd
TW201609145A (zh)	2013-12-25	2016-03-16	參天製藥股份有限公司	注射劑及形成緩釋（ｄｅｐｏｔ）之方法
HK1252159A1 (zh) *	2015-08-25	2019-05-17	参天制药株式会社	[4-(1，3，3-三甲基-2-氧代-3，4-二氢-1h-喹喔啉-7-基)苯氧基]乙基氧基化合物或其盐
EP3639854B1 (en)	2017-06-16	2026-01-07	The Doshisha	Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
WO2018230713A1 (ja)	2017-06-16	2018-12-20	学校法人同志社	カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
HRP20221020T1 (hr) *	2018-07-20	2022-11-11	Grünenthal GmbH	Supstituirani derivati triazolo kinoksalina
AR117951A1 (es)	2018-07-20	2021-09-08	Gruenenthal Gmbh	Derivados de triazolquinoxalina adicionalmente sustituidos
AU2024387082A1 (en)	2023-11-21	2026-06-04	Fmc Corporation	Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2164639T3 (es)	1991-04-15	2002-03-01	Aventis Pharma Gmbh	Quinoxalinas, procedimiento para su preparacion y su empleo.
US6369057B1 (en)	1991-04-15	2002-04-09	Aventis Pharma Deutschland Gmbh	Quinoxalines, processes for their preparation and their use
PT784054E (pt) *	1994-09-27	2002-05-31	Yamanouchi Pharma Co Ltd	Derivados de tetraidroquinoxalinadiona 1,2,3,4 e sua utilizacao como antagonistas do receptor glutamato
WO1997020578A1 (en)	1995-12-04	1997-06-12	University Of Miami	Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6340758B1 (en)	1997-05-16	2002-01-22	Warner-Lambert Company	Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
ES2246292T3 (es)	2000-10-30	2006-02-16	Pfizer Products Inc.	Moduladores de receptor glucocorticoide.
CA2523743A1 (en)	2003-04-30	2004-11-18	The Institutes For Pharmaceutical Discovery, Llc	Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
US7235662B2 (en)	2003-06-11	2007-06-26	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor and method
JPWO2005085416A1 (ja)	2004-03-04	2008-01-24	独立行政法人理化学研究所	糸状菌特異的抗菌剤のスクリーニング方法及びそのためのキット
RU2007107177A (ru)	2004-07-28	2008-09-10	Айрм Ллк (Bm)	Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
US8017775B2 (en)	2005-09-14	2011-09-13	Santen Pharmaceutical Co., Ltd.	1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity
CN101400659B (zh) *	2006-03-14	2012-02-29	参天制药株式会社	具有糖皮质激素受体结合活性的新型1，2，3，4-四氢喹喔啉衍生物
JP5054996B2 (ja) *	2006-03-14	2012-10-24	参天製薬株式会社	グルココルチコイド受容体結合活性を有する新規１，２，３，４−テトラヒドロキノキサリン誘導体
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
KR20090086539A (ko)	2006-11-14	2009-08-13	산텐 세이야꾸 가부시키가이샤	(치환 페닐 또는 치환 복소환) 카르보닐옥시 저급 알킬기와 에스테르 구조를 도입한 페닐기를 치환기로서 갖는 신규 1,2-디히드로퀴놀린 유도체
WO2008111632A1 (ja)	2007-03-13	2008-09-18	Santen Pharmaceutical Co., Ltd.	２，２，４－トリメチル－６－フェニル－１，２－ジヒドロキノリン誘導体からなるグルココルチコイド受容体アゴニスト
EP2151436B1 (en) *	2007-05-29	2013-04-24	Santen Pharmaceutical Co., Ltd	Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
JP2009084273A (ja)	2007-09-13	2009-04-23	Santen Pharmaceut Co Ltd	１，３，３−トリメチル−７−フェニル−３，４−ジヒドロ−１ｈ−キノキサリン−２−オン誘導体からなるグルココルチコイド受容体アゴニスト
WO2009035068A1 (ja)	2007-09-13	2009-03-19	Santen Pharmaceutical Co., Ltd.	新規１，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体

2008
- 2008-05-29 EP EP08764835.8A patent/EP2151436B1/en not_active Not-in-force
- 2008-05-29 MX MX2009012885A patent/MX2009012885A/es active IP Right Grant
- 2008-05-29 PL PL08764835T patent/PL2151436T3/pl unknown
- 2008-05-29 US US12/451,653 patent/US8193187B2/en not_active Expired - Fee Related
- 2008-05-29 CN CN2008800179279A patent/CN101679317B/zh not_active Expired - Fee Related
- 2008-05-29 NZ NZ581666A patent/NZ581666A/en not_active IP Right Cessation
- 2008-05-29 KR KR1020097024711A patent/KR20100022456A/ko not_active Ceased
- 2008-05-29 AU AU2008255733A patent/AU2008255733B8/en not_active Ceased
- 2008-05-29 JP JP2008140300A patent/JP5183302B2/ja not_active Expired - Fee Related
- 2008-05-29 RU RU2009149185/04A patent/RU2498980C2/ru not_active IP Right Cessation
- 2008-05-29 BR BRPI0811262-2A2A patent/BRPI0811262A2/pt not_active IP Right Cessation
- 2008-05-29 CA CA002687948A patent/CA2687948A1/en not_active Abandoned
- 2008-05-29 ES ES08764835T patent/ES2419239T3/es active Active
- 2008-05-29 WO PCT/JP2008/059866 patent/WO2008146871A1/ja not_active Ceased
2012
- 2012-02-02 US US13/364,680 patent/US8569493B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
RU2009149185A (ru)	2011-07-10
US8569493B2 (en)	2013-10-29
US20120129866A1 (en)	2012-05-24
US8193187B2 (en)	2012-06-05
BRPI0811262A2 (pt)	2014-11-04
AU2008255733B2 (en)	2013-06-06
AU2008255733B8 (en)	2013-06-13
MX2009012885A (es)	2009-12-10
CN101679317A (zh)	2010-03-24
NZ581666A (en)	2011-06-30
EP2151436A1 (en)	2010-02-10
AU2008255733A8 (en)	2013-06-13
JP5183302B2 (ja)	2013-04-17
US20100137307A1 (en)	2010-06-03
CA2687948A1 (en)	2008-12-04
AU2008255733A1 (en)	2008-12-04
JP2009007344A (ja)	2009-01-15
RU2498980C2 (ru)	2013-11-20
EP2151436A4 (en)	2011-08-03
WO2008146871A1 (ja)	2008-12-04
EP2151436B1 (en)	2013-04-24
KR20100022456A (ko)	2010-03-02
ES2419239T3 (es)	2013-08-20
CN101679317B (zh)	2012-10-31

Publication	Publication Date	Title
EP2151436A4 (en)	2011-08-03	NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING SUBSTITUTE A PHENYL GROUP IN WHICH IS INTRODUCED A SULFONIC ACID ESTER STRUCTURE OR A SULFONIC ACID AMIDE STRUCTURE AND HAVING A SULFONIC ACID GLUCOCORTICOID RECEPTOR BINDING
IL204621A0 (en)	2010-11-30	Bicyclic - ?? - amino acid derivatives, compositions comprising the same and uses thereof
IL203099A (en)	2014-01-30	Acidic Acid (s) - Optically active aryloxypropionic, methods of preparation and herbicide-containing preparations
IL213747A0 (en)	2011-07-31	Fatty acid amide hydrolase inhibitor compounds, compositions comprising the same and uses thereof
ZA200905630B (en)	2011-06-29	Stable digestive enzyme compositions
IL189394A0 (en)	2008-06-05	Substituted pyrazolecarboxylic acid anilide derivatives and agricultural compositions containing the same
PT2225238E (pt)	2014-12-18	Derivados de amidas do ácido 6,7-di-hidro-5h-imidazo[1,2- a]imidazol-3-carboxílico
SMT201400123B (it)	2014-11-10	Imidazo[1,2B]piridazine sostituite come inibitori di trk-chinasi
WO2007106746A3 (en)	2008-02-28	Formulations for ecallantide
SI1995242T1 (sl)	2013-01-31	Nov derivat 1,2,3,4-tetrahidrokinoksalina z aktivnostjo vezanja glukokortikoidnega receptorja
ZA200807862B (en)	2009-06-24	Azolopyrimidines as inhibitors of cannabinoid 1 activity
PL2085387T3 (pl)	2013-09-30	Nowe pochodne 1,2-dihydrochinoliny zawierające jako podstawniki fenylochalkogeno-podstawioną niższą grupę alkilową oraz wprowadzoną przez ester grupę fenylową
ZA201002169B (en)	2011-05-25	High concentration chitosan-nucleic acid polyplex compositions
BRPI0922489A2 (pt)	2015-12-15	amida de ácido 4-(1,2,3,4-tetrahidroisoquinolina-2-il)-4-oxobutírico como modulares de kcnq2/3
ZA201004554B (en)	2011-09-28	3-substituted-4-oxo-3,4-dihydro-imidazo-[5,1-d] [1,2,3,5]-tetrazine-8-carboxylic acid amides as anticancer agents
IL197714A0 (en)	2009-12-24	2-pyridinecarboxamide derivative having gk-activating activity
IL201921A0 (en)	2010-06-16	1,3-dihydroimidazol-2-thione derivative as inhibitors of dopamine-beta-hydroxylase
ZA201007184B (en)	2011-06-29	Cyclopentylacrylic acid amide derivative
EP2133339A4 (en)	2010-04-21	NOVEL (2-AMINOPHENYL) PYRIDINECARBOXAMIDE DERIVATIVE HAVING UREA STRUCTURE
EP2129672A4 (en)	2009-12-09	ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE
IL215153A0 (en)	2011-12-29	Amide derivative compounds, compositions comprising the same and uses there of
PL1868984T3 (pl)	2018-03-30	Związki estrowe kwasu benzoesowego oraz związane z nimi kompozycje, wykorzystanie i sposoby
WO2009003672A3 (en)	2009-03-12	Novel microbiocides
EP2327699A4 (en)	2011-12-28	GLUCOCORTICOIDREZEPTORAGONIST WITH A NOVEL 1,2,3,4-TETRAHYDROCHINOXALINE DERIVATIVE WITH A PHENYL GROUP WITH A SULFURIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS A SUBSTITUENT
IL194094A0 (en)	2009-08-03	Stable pharmacuetical compositions of 2-aza-bicyclol[3.3.0]-octane-3-carboxylic acid derivatives